PDF herunterladen
Kinder- und Jugendmedizin 2021; 21(01): 27-35
DOI: 10.1055/a-1329-1815
Schwerpunkt

Im Falle des Einsatzes eines Calcineurininhibitorsbei komplizierten Verläufen des nephrotischen Syndroms im Kindesalter

Ciclosporin A oder Tacrolimus – die Qual der Wahl?
Rasmus Ehren∗
1   Universität zu Köln, Medizinische Fakultät und Uniklinik Köln, Klinik und Poliklinik für Kinder- und Jugendmedizin
,
Lutz T. Weber∗
1   Universität zu Köln, Medizinische Fakultät und Uniklinik Köln, Klinik und Poliklinik für Kinder- und Jugendmedizin
› Institutsangaben
› Weitere Informationen
    Lizenzen und Reprints

ZUSAMMENFASSUNG

Oft wird zur Behandlung eines kompliziert verlaufenden nephrotischen Syndroms des Kindesalters eine immunsuppressive Dauertherapie eingesetzt. Als first-line-Therapie beim kompliziert verlaufenden steroidsensiblen nephrotischen Syndrom hat sich in Deutschland in den letzten Jahren Mycophenlatmofetil etabliert. Muss aber ein Calcineurininhibitor eingesetzt werden, kann zwischen Ciclosporin A und Tacrolimus gewählt werden. In dieser Übersichtsarbeit werden die Vor- und Nachteile beider Therapien beleuchtet, die Indikationsstellung bei den unterschiedlichen Verlaufsformen des nephrotischen Syndroms erläutert und mögliche Entscheidungshilfen bei der Wahl des Calcineurininhibitors gegeben.

Schlüsselwörter

Akute Nierenschädigung - Neonaten - chronisches Nierenversagen

Keywords

Acute kidney injury - newborn - chronic kidney disease


Publikationsverlauf

Artikel online veröffentlicht:
25. Februar 2021

© 2021. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • Literatur

  • 1 Webb NJA, Woolley RL, Lambe T. et al Long term tapering versus standard prednisolone treatment for first episode of childhood nephrotic syndrome: phase III randomised controlled trial and economic evaluation. BMJ 2019; 365: 1800
    CrossrefGoogle Scholar
  • 2 Deschênes G, Vivarelli M, Peruzzi L. ESPN Working Group on Idiopathic Nephrotic Syndrome. Variability of diagnostic criteria and treatment of idiopathic nephrotic syndrome across European countries. Eur J Pediatr 2017; 176 (05) 647-654
    CrossrefPubMedGoogle Scholar
  • 3 Gellermann J, Weber L, Pape L. et al Mycophenolate mofetil versus cyclosporin A in children with frequently relapsing nephrotic syndrome. J Am Soc Nephrol JASN 2013; 24 (10) 1689-1697
    CrossrefPubMedGoogle Scholar
  • 4 Hogg RJ, Fitzgibbons L, Bruick J. et al Mycophenolate mofetil in children with frequently relapsing nephrotic syndrome: a report from the Southwest Pediatric Nephrology Study Group. Clin J Am Soc Nephrol CJASN 2006; 1 (06) 1173-1178
    CrossrefPubMedGoogle Scholar
  • 5 Dehoux L, Hogan J, Dossier C. et al Mycophenolate mofetil in steroid-dependent idiopathic nephrotic syndrome. Pediatr Nephrol Berl Ger 2016; 31 (11) 2095-2101
    CrossrefGoogle Scholar
  • 6 Sinha A, Puraswani M, Kalaivani M. et al Efficacy and safety of mycophenolate mofetil versus levamisole in frequently relapsing nephrotic syndrome: an open-label randomized controlled trial. Kidney Int 2019; 95 (01) 210-218
    CrossrefPubMedGoogle Scholar
  • 7 Sinha A, Gupta A, Kalaivani M. et al Mycophenolate mofetil is inferior to tacrolimus in sustaining remission in children with idiopathic steroid-resistant nephrotic syndrome. Kidney Int 2017; 92 (01) 248-257
    CrossrefPubMedGoogle Scholar
  • 8 Hackl A, Ehren R, Weber LT. Effect of mycophenolic acid in experimental, nontransplant glomerular diseases: new mechanisms beyond immune cells. Pediatr Nephrol. 2016: 16 June 2016
    Google Scholar
  • 9 Fujinaga S, Ohtomo Y, Hirano D. et al Mycophenolate mofetil therapy for childhood-onset steroid dependent nephrotic syndrome after long-term cyclosporine: extended experience in a single center. Clin Nephrol 2009; 72 (04) 268-273
    PubMedGoogle Scholar
  • 10 Dorresteijn EM, Kist-van Holthe JE, Levtchenko EN. et al Mycophenolate mofetil versus cyclosporine for remission maintenance in nephrotic syndrome. Pediatr 2008; 23 (11) 2013-2020
    Google Scholar
  • 11 Hooks MA. Tacrolimus, a new immunosuppressant – a review of the literature. Ann Pharmacother 1994; 28 (04) 501-511
    CrossrefPubMedGoogle Scholar
  • 12 Kolars JC, Awni WM, Merion RM. et al First-pass metabolism of cyclosporin by the gut. Lancet 1991; 338 8781 1488-1490
    CrossrefPubMedGoogle Scholar
  • 13 Liu J, Farmer JD, Lane WS. et al Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell 1991; 66 (04) 807-815
    CrossrefPubMedGoogle Scholar
  • 14 Wiederrecht G, Lam E, Hung S. et al The mechanism of action of FK-506 and cyclosporin A. Ann N Y Acad Sci 1993; 696: 9-19
    CrossrefPubMedGoogle Scholar
  • 15 Liao R, Liu Q, Zheng Z. et al Tacrolimus Protects Podocytes from Injury in Lupus Nephritis Partly by Stabilizing the Cytoskeleton and Inhibiting Podocyte Apoptosis. PloS One 2015; 10 (07) e0132724
    CrossrefPubMedGoogle Scholar
  • 16 Shen X, Jiang H, Ying M. et al Calcineurin inhibitors cyclosporin A and tacrolimus protect against podocyte injury induced by puromycin aminonucleoside in rodent models. Sci Rep 2016: 6-32087
    Google Scholar
  • 17 Faul C, Donnelly M, Merscher-Gomez S. et al The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A. Nat Med 2008; 14 (09) 931-938
    CrossrefPubMedGoogle Scholar
  • 18 Zhang Q, Shi S-F, Zhu L. et al Tacrolimus improves the proteinuria remission in patients with refractory IgA nephropathy. Am J Nephrol 2012; 35 (04) 312-320
    CrossrefPubMedGoogle Scholar
  • 19 Hoorn EJ, Walsh SB, McCormick JA. et al The calcineurin inhibitor tacrolimus activates the renal sodium chloride cotransporter to cause hypertension. Nat Med 2011; 17 (10) 1304-1309
    CrossrefPubMedGoogle Scholar
  • 20 Muduma G, Saunders R, Odeyemi I, Pollock RF. Systematic Review and Meta-Analysis of Tacrolimus versus Ciclosporin as Primary Immunosuppression After Liver Transplant. PloS One 2016; 11 (11) e0160421
    CrossrefPubMedGoogle Scholar
  • 21 U. S. Multicenter FK506 Liver Study Group. A comparison of tacrolimus (FK 506) and cyclosporine for immunosuppression in liver transplantation. N Engl J Med 1994; 331 (17) 1110-1115
    CrossrefPubMedGoogle Scholar
  • 22 Gijtenbeek JM, van den Bent MJ, Vecht CJ. Cyclosporine neurotoxicity: a review. J Neurol 1999; 246 (05) 339-346
    CrossrefPubMedGoogle Scholar
  • 23 Eidelman BH, Abu-Elmagd K, Wilson J. et al Neurologic complications of FK 506. Transplant Proc 1991; 23 (06) 3175-3178
    PubMedGoogle Scholar
  • 24 Choudhry S, Bagga A, Hari P. et al Efficacy and safety of tacrolimus versus cyclosporine in children with steroid-resistant nephrotic syndrome: a randomized controlled trial. Am J Kidney Dis Off J Natl Kidney Found 2009; 53 (05) 760-769
    CrossrefPubMedGoogle Scholar
  • 25 Vogd J, Hackl A, Habbig S. et al Discontinuation of maintenance therapy in frequently relapsing nephrotic syndrome. Clin Nephrol 2019; 91 (01) 25-31
    CrossrefPubMedGoogle Scholar
  • 26 Ishikura K, Yoshikawa N, Hattori S. et al Treatment with microemulsified cyclosporine in children with frequently relapsing nephrotic syndrome. Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc – Eur Ren Assoc 2010; 25 (12) 3956-3962
    Google Scholar
  • 27 Ishikura K, Ikeda M, Hattori S. et al Effective and safe treatment with cyclosporine in nephrotic children: a prospective, randomized multicenter trial. Kidney Int 2008; 73 (10) 1167-1173
    CrossrefPubMedGoogle Scholar
  • 28 Basu B, Sander A, Roy B. et al Efficacy of Rituximab vs Tacrolimus in Pediatric Corticosteroid-Dependent Nephrotic Syndrome: A Randomized Clinical Trial. JAMA Pediatr 2018; 172 (08) 757-764
    CrossrefPubMedGoogle Scholar
  • 29 Sinha MD, MacLeod R, Rigby E, Clark AGB. Treatment of severe steroid-dependent nephrotic syndrome (SDNS) in children with tacrolimus. Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc – Eur Ren Assoc 2006; 21 (07) 1848-1854
    Google Scholar
  • 30 Wang W, Xia Y, Mao J. et al Treatment of tacrolimus or cyclosporine A in children with idiopathic nephrotic syndrome. Pediatr 2012; 27 (11) 2073-2079
    Google Scholar
  • 31 van Boekel GAJ, Aarnoutse RE, van der Heijden JJ. et al Effect of mild diarrhea on tacrolimus exposure. Transplantation 2012; 94 (07) 763-767
    CrossrefPubMedGoogle Scholar
  • 32 Medeiros M, Valverde S, Del Moral I. et al Are Tacrolimus Pharmacokinetics Affected by Nephrotic Stage?. Ther Drug Monit 2016; 38 (03) 288-292
    CrossrefPubMedGoogle Scholar
  • 33 Prasad N, Manjunath R, Rangaswamy D. et al Efficacy and Safety of Cyclosporine versus Tacrolimus in Steroid and Cyclophosphamide Resistant Nephrotic Syndrome: A Prospective Study. Indian J Nephrol 2018; 28 (01) 46-52
    CrossrefPubMedGoogle Scholar
  • 34 Ahmed HM. Tacrolimus can induce remission in cyclosporine and mycophenolate mofetil resistant pediatric onset nephrotic syndrome. Iran J Kidney Dis 2019; 13 (05) 322-327
    PubMedGoogle Scholar
  • 35 Querfeld U, Dötsch J, Gellermann J. et al Diagnostik und Therapie des idiopathischen nephrotischen Syndroms im Kindesalter: Zusammenfassung der S2e-Leitlinie AWMF-Registernummer 166–001 federführend: Gesellschaft für Pädiatrische Nephrologie. Monatsschr Kinderheilkd. 2017: 165
    Google Scholar